Atlas Trials

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Clinical trial NCT05828511 · RECRUITING

Trial details

NCT number
NCT05828511
Sponsor
Regeneron Pharmaceuticals
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2023-12-19
Primary completion
2035-11-02
Enrollment
149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.